Patrick P. Zarrinkar

12.8k total citations · 4 hit papers
34 papers, 5.0k citations indexed

About

Patrick P. Zarrinkar is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Patrick P. Zarrinkar has authored 34 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 15 papers in Hematology and 10 papers in Genetics. Recurrent topics in Patrick P. Zarrinkar's work include Chronic Myeloid Leukemia Treatments (12 papers), Acute Myeloid Leukemia Research (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Patrick P. Zarrinkar is often cited by papers focused on Chronic Myeloid Leukemia Treatments (12 papers), Acute Myeloid Leukemia Research (10 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Patrick P. Zarrinkar collaborates with scholars based in United States, United Kingdom and Switzerland. Patrick P. Zarrinkar's co-authors include Daniel K. Treiber, James R. Williamson, Jeremy P. Hunt, Gabriel Pallares, Lisa Wodicka, Pietro Ciceri, Mindy I. Davis, Sanna Herrgård, Michael Höcker and David J. Lockhart and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Patrick P. Zarrinkar

34 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comprehensive analysis of kinase inhibitor selectivity

2011 1.6k citations Mindy I. Davis, Jeremy P. Hunt et al. Nature Biotechnology profile →
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

2001 546 citations John Welsh, Patrick P. Zarrinkar et al. profile →
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

2012 542 citations Catherine C. Smith, Qi Wang et al. Nature profile →
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

2009 474 citations Patrick P. Zarrinkar, Ruwanthi N. Gunawardane et al. Blood profile →

Peers

Countries citing papers authored by Patrick P. Zarrinkar

Since Specialization

Citations

This map shows the geographic impact of Patrick P. Zarrinkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick P. Zarrinkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick P. Zarrinkar more than expected).

Fields of papers citing papers by Patrick P. Zarrinkar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick P. Zarrinkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick P. Zarrinkar. The network helps show where Patrick P. Zarrinkar may publish in the future.

Co-authorship network of co-authors of Patrick P. Zarrinkar

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick P. Zarrinkar. A scholar is included among the top collaborators of Patrick P. Zarrinkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick P. Zarrinkar. Patrick P. Zarrinkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors 2018 ·Scientific Reports ·Rasmus Hansen, Sarah J. Firdaus, Shuangwei Li, Matthew R. Janes, Jingchuan Zhang, Yi Liu, Patrick P. Zarrinkar	6
2	The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors 2018 ·Nature Structural & Molecular Biology ·Rasmus Hansen, Ulf Peters, Anjali Babbar, Yuching Chen, Jun Feng, Matthew R. Janes, Lian‐Sheng Li, Pingda Ren, Yi Liu, Patrick P. Zarrinkar	100
3	Abstract LB-A27: A novel small molecule menin-MLL inhibitor for potential treatment of MLL-rearranged leukemias and NPM1/DNMT3A-mutant AML 2018 ·Molecular Cancer Therapeutics ·Francis Burrows, (unknown), Linda Kessler, Shuangwei Li, Jingchuan Zhang, Patrick P. Zarrinkar, Lian‐Sheng Li, Tomasz Cierpicki, Jolanta Grembecka, Pingda Ren, Yi Liu	11
4	Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine 2016 ·BMC Genomics ·Zhou Zhu, Nathan T. Ihle, Paul A. Rejto, Patrick P. Zarrinkar	7
5	Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors 2015 ·Bioorganic & Medicinal Chemistry Letters ·Gang Liu, Sunny Abraham, Xing Liu, Shimin Xu, (unknown), (unknown), (unknown), Daniel Brigham, (unknown), Darren E. Insko, Michael F. Gardner, Patrick P. Zarrinkar, (unknown), Barbara Belli, Robert C. Armstrong, Mark W. Holladay	16
6	Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia breakdown → 2012 ·Nature ·Catherine C. Smith, Qi Wang, Chen-Shan Chin, Sara Salerno, Lauren E. Damon, Mark J. Levis, Alexander E. Perl, Kevin Travers, Susana Wang, Jeremy P. Hunt, Patrick P. Zarrinkar, Eric E. Schadt, Andrew Kasarskis, John Kuriyan, Neil P. Shah	542
7	Comprehensive analysis of kinase inhibitor selectivity breakdown → 2011 ·Nature Biotechnology ·Mindy I. Davis, Jeremy P. Hunt, Sanna Herrgård, Pietro Ciceri, Lisa Wodicka, Gabriel Pallares, Michael Höcker, Daniel K. Treiber, Patrick P. Zarrinkar	1639
8	High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors 2011 ·Chemistry & Biology ·Chandrasekhar V. Miduturu, Xianming Deng, Nicholas Kwiatkowski, Wannian Yang, Laurent Brault, P. Filippakopoulos, Eunah Chung, Qingkai Yang, Juerg Schwaller, Stefan Knapp, Randall W. King, Jiing‐Dwan Lee, Sanna Herrgård, Patrick P. Zarrinkar, Nathanael S. Gray	95
9	Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry 2010 ·Chemistry & Biology ·Lisa Wodicka, Pietro Ciceri, Mindy I. Davis, Jeremy P. Hunt, M. Brawner Floyd, Sara Salerno, (unknown), Julia M. Ford, Robert C. Armstrong, Patrick P. Zarrinkar, Daniel K. Treiber	82
10	Abstract 3619: Inhibition of FLT3 autophosphorylation and downstream signaling both in vitro and in vivo by AC220, a second generation potent and selective FLT3 inhibitor 2010 ·Cancer Research ·Ruwanthi N. Gunawardane, (unknown), (unknown), Daniel Brigham, Jill M. Ricono, Patrick P. Zarrinkar, Shripad V. Bhagwat, Barbara Belli, Wendell Wierenga, Robert Armstrong	1
11	Abstract #1787: Characterization of the biochemical and cellular activity of the second-generation FLT3 inhibitor AC220 2009 ·Cancer Research ·Patrick P. Zarrinkar, Robert Armstrong, Ruwanthi N. Gunawardane, Joyce James, Mazen W. Karaman, Shripad S. Bhagwat	1
12	Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors 2009 ·Bioorganic & Medicinal Chemistry Letters ·Hitesh Patel, Robert M. Grotzfeld, Andiliy Lai, (unknown), (unknown), Qi Chao, Kelly G. Sprankle, Todd A. Carter, (unknown), Miles A. Fabian, Joyce James, Daniel K. Treiber, David J. Lockhart, Patrick P. Zarrinkar, Shripad S. Bhagwat	26
13	Tuning a Three-Component Reaction For Trapping Kinase Substrate Complexes 2008 ·Journal of the American Chemical Society ·(unknown), Dustin J. Maly, Markus A. Seeliger, Miles A. Fabian, William Biggs, David J. Lockhart, Patrick P. Zarrinkar, John Kuriyan, Kevan M. Shokat	63
14	High-throughput kinase profiling as a platform for drug discovery 2008 ·Nature Reviews Drug Discovery ·David Goldstein, Nathanael S. Gray, Patrick P. Zarrinkar	162
15	Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor 2008 ·Blood ·Jörge E. Cortes, Darejan Ghirdaladze, James M. Foran, Marcel P. Devetten, Mamia Zodelava, Mark J. Levis, (unknown), James A. Joyce, Patrick P. Zarrinkar, Robert Corringham	11
16	Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680 2006 ·Cancer Research ·Matthew A. Young, Neil P. Shah, Luke H. Chao, Markus A. Seeliger, (unknown), William Biggs, Daniel K. Treiber, Hitesh Patel, Patrick P. Zarrinkar, David J. Lockhart, Charles L. Sawyers, John Kuriyan	211
17	Arrays of Arrays for High-Throughput Gene Expression Profiling 2001 ·Genome Research ·Patrick P. Zarrinkar, James Mainquist, Matthew T. Zamora, David L. Stern, John Welsh, Lisa M. Sapinoso, Garret M. Hampton, David J. Lockhart	30
18	Arrays of Arrays for High-Throughput Gene Expression Profiling 2001 ·Genome Research ·Patrick P. Zarrinkar	20
19	Kinetic Intermediates Trapped by Native Interactions in RNA Folding 1998 ·Science ·Daniel K. Treiber, Martha Rook, Patrick P. Zarrinkar, James R. Williamson	185
20	The kinetic folding pathway of the Tetrahymena ribozyme reveals possible similarities between RNA and protein folding 1996 ·Nature Structural Biology ·Patrick P. Zarrinkar, James R. Williamson	93

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact